Portland, OR -- (SBWIRE) -- 08/23/2017 -- Allied Market Research has recently published an in-depth report on the global oncology drugs market. The global oncology drugs market valued at $78,238.9 million in 2015 is expected to garner $111.9 billion by 2020. The market is anticipated to exhibit a compound annual growth rate of 7.1% during the forecast period 2013–2020. The recent advancements in the biological therapies have propelled the growth of the global oncology drugs market.

The report highlights the key drivers, opportunities, threats, and restraints faced by the established players in the market. The quantitative and qualitative analysis presented in the report gives a detailed understanding of the current and future market trends prevalent in the market. On analyzing the global oncology drugs market using Porter's Five Forces Analysis, the bargaining powers of the buyers was found to be low whereas that of suppliers is moderate. The low threat from new entrants and the moderate threat from the substitute products facilitate the growth of the organizations.

Get a Sample Copy of this report @ https://www.alliedmarketresearch.com/request-sample/121

There has been a surge in the detection of cancer in the recent years. The rising incidence and prevalence of various types of cancer have fuelled the growth of the global oncology drugs market. The growing demand for biological and targeted drug therapies, expiration of key patents and increasing influence biosimilars have boosted the growth of the global oncological drugs market. Acquisitions and collaborations have a huge impact on the global market and its trends, revenue, and the developments. The high cost involved in the development of drugs added with the threat of failure hinder the growth of the market. Another limiting factor acting as an obstacle to the growth of the global market is the increasing adverse side effects of anticancer drug therapy. Advancement in the research and development of anti-cancer drugs will present a wide array of opportunities to the new entrants and potential investors. Progression in technology will lower the cost incurred and will lead to the growth of the market.

The global oncology drugs market is segmented based on the therapeutic modalities, cancer types, and the geography. The therapeutic modalities include chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. Cancer may spread in the form of blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, respiratory/lung cancer, or skin cancer. Based on geography, the presence of the oncology drugs market in North America, Europe, Asia-Pacific, and LAMEA has been analyzed within the scope of the study.

Request Report Sample @ https://www.alliedmarketresearch.com/purchase-enquiry/121

The leading players in the global oncology drugs market include Amgen Inc., Johnson and Johnson, Roche Diagnostics, GlaxoSmithKline PLC, Merck & Company, Novartis AG, Pfizer, Sanofi, Eli Lilly and Company, and Celgene Corporation. The report comprises of the company overview, their financial performance and the business segments that they operate in. SWOT analysis of the organizations highlights their strengths, weaknesses, wide range of opportunities and the threats faced by them. The key strategic moves deployed by the prominent players are contained in the report to give the stakeholders a critical insight of the market.

Key points of the report

- The report is a compilation of the vast data sets of the global oncology drugs market acquired from an extensive primary and secondary research by expert analysts using analyst tools and models.

- The report presents a comprehensive analysis of all the factors that boost or restrict the growth of the global market.

- Roche Diagnostics, Novartis AG, and Celgene Corporation are the top three players contributing to approximately 60% of the total market share.

- The key player positioning and the winning strategies adopted by them assist in understanding the market scenario and make informed decisions.